cover image: 18-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer / : EBS 7-20, version 2

Premium

20.500.12592/j73rgs

18-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer / : EBS 7-20, version 2

5 Oct 2012

"Questions: What is the role of 18-Fluorodeoxyglucose (18FDG) Positron Emission Tomography (PET) in: 1. The diagnosis of solitary pulmonary nodules (SPN)? 2. The staging of primary non-small cell lung cancer (NSCLC) at initial diagnosis? 3. The staging of primary small cell lung cancer (SCLC)? Outcomes of interest include accuracy measures of imaging and the impact of PET on patient management and patient outcomes"--Page 1.
health lung cancer science and technology research cancer medical imaging lungs medical research medicine lung neoplasms evidence-based medicine therapy clinical trial biopsy clinical medicine health treatment health sciences government health care medical specialties sensitivity diseases and conditions imaging cancer staging hta positron-emission tomography fluorodeoxyglucose f18 positron emission tomography metastases workup fdg-pet nsclc tomography, emission
Pages
60
Published in
Ottawa, Ontario

Related Topics

All